Patent Law Weblog
recent posts
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
- BioNTech Sues Moderna over mRNA Vaccine Technology
about
Category: Patent Profiles
-
By Donald Zuhn — SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release,…
-
By Donald Zuhn — Osprey Pharmaceuticals Ltd. announced today that it had been granted U.S. Patent Nos. 7,157,418; 7,166,702; and 7,192,736. The claims of the ‘418 patent are directed to methods for treating secondary tissue damage and other inflammatory conditions and disorders using a chemokine-cell toxin conjugate, the claims of the ‘702 patent…
-
By Donald Zuhn — Last month, Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,186,542. The ‘542 patent, which relates to methods of producing reovirus from a cultured cells, was the nineteenth U.S. patent to be awarded to the Calgary-based biotech company. As we reported last week, Oncolytics was…
-
By Donald Zuhn — On April 3, 2007, Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,198,783. The ‘783 patent, which relates to methods of sensitizing neoplastic cells to irradiation by using reoviruses, is the twentieth U.S. patent to be awarded to the Calgary-based biotech company. According to the…
-
By Donald Zuhn — On Wednesday, Cell Signaling Technology, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its application entitled "Immunoaffinity Isolation of Modified Peptides from Complex Mixtures." A search of Public PAIR indicates that U.S. Application No. 10/175,486 will issue as Patent No.…
-
By Donald Zuhn — The United States Patent and Trademark Office recently issued U.S. Patent No. 7,179,484 to Azaya Therapeutics, Inc. The ‘484 patent, which relates to protein-stabilized liposomal formulations for the delivery of pharmaceutical agents, is the first U.S. patent to be awarded to the San Antonio-based pharmaceutical company. After receiving a…
-
By Jason Derry ARIUS Research Inc. has announced that two new U.S. patents relating to its anti-cancer antibody program have issued. U.S. Patent No. 7,175,846 specifically relates to methods of treating cancer using antibodies that destroy melanoma, breast, and prostate cancer cells while ignoring normal cells. Representative independent claim 2 recites: 2. A…
-
By Donald Zuhn On March 7, 2007, INEX Pharmaceuticals Corp. and Alnylam Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 09/431,594, which covers nucleic acid-lipid compositions. According to the statement released by INEX, the allowed claims "cover[] cationic liposome compositions…
-
By Christopher P. Singer On February 21, 2007 two companies announced that they had either received a Notice of Allowance or an issued patent for dermatologically related technologies. Barrier Therapeutics, Inc. announced the issuance of U.S. Patent No. 7,179,475 titled "Anhydrous Topical Skin Preparations." Barrier stated that this patent covers a formulation of…
-
By Christopher P. Singer In a February 14, 2006 press release, Idera Pharmaceuticals, Inc. announced that U.S. Patent No. 7,176,296, titled "Modulation of Oligonucleotide CpG-Mediated Immune Stimulation by Positional Modification of Nucleosides," has been granted by the U.S. Patent Office. According to Idera, the patent covers a series of compounds that comprise modifications…
Patent Docs 